OBJECTIVE: To evaluate the effect and safety of Kangfuyan Capsules () for treating pelvic inflammatory disease (PID) in patients with chronic pelvic pain (CPP) in a multicenter, randomized, controlled, double-blind, parallel-group clinical trial. METHODS: Totally, 240 PID patients with CPP were randomized into 2 groups using a computer generated random number at a 1:1 ratio from 10 hospitals in China between September 2014 and November 2015. Patients received either oral Kangfuyan Capsules or Gongyanping Capsules (, control); the regimen for both groups comprised 4 capsules (3 times daily) for 12 weeks, with follow-up visit 4 weeks after treatment. The visual analogue scale (VAS) scores, clinical responses, remarkable cure rates for each symptom, and quality of life scores were assessed at baseline, and after 1, 2, and 3 months. Adverse events were also recorded. RESULTS: The VAS scores were significantly lower (P<0.05), whereas the clinical responses, remarkable cure rates for lower abdominal pain, uterine tenderness, adnexal mass, and adnexal tenderness, and Health-related quality of life (EQ-5D) scores were higher in the Kangfuyan group than in the control group at 3 months (P<0.05). Common treatment-related adverse events included high hepatic enzyme levels, reduced hemoglobin levels, and elevated platelet counts, although all the adverse events were either mild or moderate in severity. CONCLUSION Compared with Gongyanping therapy, Kangfuyan therapy yielded markedly better analgesia effects for CPP caused by PID, with obvious long-term efficacy and good safety. (Registration No. ChiCTR190022732).
Capsules ; Chronic Pain/drug therapy* ; Double-Blind Method ; Humans ; Pelvic Pain/drug therapy* ; Quality of Life ; Treatment Outcome

Chronic prostatitis is a common disease in male. So far the etiology and pathogenesis of chronic prostatitis, particularly chronic pelvic pain syndrome (CPPS), remain to be elucidated and there is no unified recognition in the treatment of this disease. This article discusses the thoughts and methods for the diagnosis and treatment of chronic prostatitis by combination of TCM and Western medicine systematically.
Chronic Disease ; Combined Modality Therapy ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Male ; Pelvic Pain ; drug therapy ; Phytotherapy ; Prostatitis ; drug therapy

OBJECTIVE: To evaluate the efficacy and safety of essential oil treatment for type III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). METHODS: A randomized controlled trial was conducted from December 2014 to October 2015. Seventy type III CP/CPPS patients were assigned to the essential oil group (35 cases) or almond placebo oil control group (35 cases) by a random number table. The oil was smeared by self-massage on the suprapubic and sacral region once a day for 4 weeks. The National Institutes of Health Chronic Prostatitis Syndrome Index (NIH-CPSI) and expressed prostatic secretions (EPS) were examined. The primary outcome was NIH-CPSI pain domain. The secondary outcomes included other NIH-CPSI domains and laboratory examinations of EPS. Adverse events were also observed. RESULTS: Sixty-six subjects completed the full 4-week treatment. There was no significant difference between almond oil control and essential oil groups in terms of the total score of NIH-CPSI, pain, quality of life and urination domain scores of NIH-CPSI and EPS examinations (P>0.05). In the essential oil group, pain between rectum and testicles (perineum) in the domain of pain or discomfort was significantly reduced at week 2 and week 4 compared with almond oil control group (P<0.01). No serious adverse events occurred. CONCLUSION The essential oil may reduce the pain or discomfort in the perineum region in patients with CP/CPPS. (Registration No. ChiCTR-IPR-14005448).
Adult ; Chronic Pain ; drug therapy ; Humans ; Male ; Oils, Volatile ; therapeutic use ; Pelvic Pain ; drug therapy ; Pilot Projects ; Prostatitis ; drug therapy ; Syndrome ; Treatment Outcome

OBJECTIVETo evaluate the clinical efficacy of Qiantongding Decoction in the treatment of type III B prostatitis or chronic pelvic pain syndrome (CPPS).

METHODSSeventy patients with type III B prostatitis / CPPS were randomly divided into an experimental group (n = 36) and a control group (n = 34), the former treated with Qiantongding Decoction, and the latter with oral Indometacin, both for a month. Then their scores on Pelvic Pain Symptom Survey and NIH-CPSI were documented and compared.

RESULTSAn obvious improvement was observed in both groups after the treatment, with significant differences from pre-treatment (P < 0.05), and the experimental group showed a significantly better alleviation of pain than the control (P < 0.05).

CONCLUSIONQiantongding Decoction has an obvious therapeutic effect on type III B prostatitis / CPPS.

Adult ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Male ; Middle Aged ; Pelvic Pain ; drug therapy ; Phytotherapy ; Prostatitis ; drug therapy ; Treatment Outcome

Endodermal sinus tumor (EST) has also been referred to as yolk sac carcinoma because they are derived from the primitive yolk sac. These lesions are the third most frequent malignant germ cell tumor of the ovary. Patient with EST have a median age of 18 years, but approximately one third of the patients are premenarchal at the time of initial presentation. Abdominal and/or pelvic pain is the most frequent presenting symptom, most EST secrete AFP. Radical surgery has not been helpful, but recent advances in treating the EST of the ovary with the combination chemotherapy after unilateral salpingo-oophorectomy result in improvement of the prognosis. We had experienced a case of endodermal sinus tumor of 36 years old woman. So, we report this case with brief review of the literature.
Adult ; Drug Therapy, Combination* ; Endoderm* ; Endodermal Sinus Tumor* ; Female ; Humans ; Neoplasms, Germ Cell and Embryonal ; Ovary* ; Pelvic Pain ; Prognosis ; Yolk Sac

Saw palmetto fruit extract (SPE), as a herbal product, is widely used for the treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Recent studies show that SPE also has some therapeutic effects on chronic prostatitis, prostate cancer, sexual dysfunction, and so on. This article presents an overview on the application of SPE in the treatment of BPH, prostate cancer, and chronic prostatitis/chronic pelvic pain syndrome, with a discussion on its action mechanisms.
Chronic Disease ; Fruit ; chemistry ; Humans ; Lower Urinary Tract Symptoms ; drug therapy ; Male ; Pelvic Pain ; drug therapy ; Plant Extracts ; therapeutic use ; Prostatic Diseases ; drug therapy ; Prostatic Hyperplasia ; drug therapy ; Prostatic Neoplasms ; drug therapy ; Prostatitis ; drug therapy ; Syndrome

OBJECTIVETo evaluate the efficacy and safety of intraprostatic injection of Chuanshentong in the treatment of chronic abacterial prostatitis/chronic pelvic pain syndrome(CAP/CPPS).

METHODSRandomized, double blinded, placebo controlled trials were carried out from September 2002 to March 2003. A total of 38 patients with diagnosed CAP/CPPS, 24 experimental and 14 controls, were analyzed. In the trial group, 6 ml of mixed solution of Chuanshentong and lidocaine was transperineally injected into one lobe of the prostate, once a day for 6 days. Likewise, the control group was treated with placebo containing lidocaine. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index(CPSI) after a 6-week follow-up. The main semen parameters before and after 3-month treatment were compared.

RESULTSIn the trial group, 13 cases (56.5%) were completely cured, 5 cases(21.7%) showed remarkable effect, and 4 cases (17.4%) were improved. While in the control group, effectiveness was shown in only 2 cases (15.4%), and improvement in 3 cases (23%). CPSI scores decreased significantly after treatment(95% of confidence interval: 17.97-23.08). Chuanshentong solution had no obvious impact on the main semen parameters. No severe adverse effects were observed.

CONCLUSIONTransperineal intraprostatic injection of Chuanshentong is a safe and effective method for the treatment of CAP/CPPS.

Adult ; Chronic Disease ; Double-Blind Method ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Humans ; Injections ; Male ; Middle Aged ; Pelvic Pain ; drug therapy ; Prostatitis ; drug therapy

OBJECTIVETo explore the effectiveness of Longjintonglin capsule in treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

METHODSOne hundred and thirty-six patients accorded with the demands of chronic prostatitis type III of National Institute of Health (NIH), among them there were 84 cases of chronic prostatitis type IIIA and 52 cases of type IIIB. All of the patients accepted oral Longjintonglin capsule for 3 tablets, 3 times per day, for 3 months. NIH- chronic prostatitis symptom index (NIH-CPSI) and counting leukocytes in expressed prostatic secretions (EPS) were used as target to evaluate the effectiveness.

RESULTSOne hundred and thirty-one cases accomplished treatment, in which there were 81 cases of type IIIA, and 50 cases of type IIIB. Overall scores of NIH-CPSI before and after treatment were(24.8 +/- 5.6) and (13.3 +/- 6.8) points respectively, which dropped significantly (average 11.5 points), (P < 0.01). The symptom scores before and after treatment were (15.4 +/- 4.3) and (8.7 +/- 3.9) respectively, which also decreased significantly (average 6.7 points), (P <0.01). The scores for quality of life before and after treatment were (9.4 +/- 3.7) and (4.6 +/- 2.7) respectively, which dropped significant (average 4.8 points) (P < 0.01). The leukocytes counts before and after treatment in patients with CP/CPPs type IIIA were (21.7 +/- 14.5)/HP and (8.8 +/- 12.6)/HP, respectively. Twenty-four cases(18.3%) got cured, 41 cases (31.3%) notable effect, 40 cases (30.5%) some effect, 26 cases (19.8%) no effect, and total effective rate was 80.1%. No apparent side effect was observed in all patients accepted treatment, especially for their kidney and hepatic function.

CONCLUSIONLongjintonglin capsule was a safe and effective medicine in treatment of CP/CPPS without significant side effect.

Adult ; Chronic Disease ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Male ; Middle Aged ; Pelvic Pain ; drug therapy ; Phytotherapy ; Prostatitis ; drug therapy ; Treatment Outcome

OBJECTIVETo assess the clinic efficacy and safety in the treatment of chronic abacterial prostatitis/chronic pelvic pain syndrome (CABP/CPPS) after intraprostatic injection of Chuanshentong.

METHODSFive milliliter of solution blending Chuanshentong and lidocaine was transperineally injected into one lobe of prostate, once a day for 6 days, for a total of 98 cases of patients who had been diagnosed as chronic abacterial prostatitis/chronic pelvic pain syndrome. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index (CPSI) after a 12 week follow-up.

RESULTSAll cases had completed the follow-up. Fifty-three cases (54.08%) were completely cured, accompanied by remarkable effective in 17 cases (17.35%) and improved in 23 cases (23.47%). The total remarkable efficacy was 71.43% and improved 94. 90%. Scores of CPSI decreased significantly compared with pre-treatment (95% confidence interval 12.85 approximately 17.91).

CONCLUSIONIt is suggested that transperineally intraprostatic injection of Chuanshentong may be a useful method for the treatment of CABP/CPPS.

Adult ; Chronic Disease ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Injections, Intralesional ; Male ; Middle Aged ; Pelvic Pain ; drug therapy ; Phytotherapy ; Prostatitis ; drug therapy

OBJECTIVETo study the therapeutic effect and safety of Longjintonglin Capsule in the treatment of type III prostatitis (chronic prostatitis/chronic pelvic pain syndrome, CP/CPPS).

METHODWe selected 240 patients with type III prostatitis according to the diagnostic standards of the American National Institute of Health (NIH) and treated them with Longjintonglin Capsule orally 3 capsules once tid for 12 weeks. Based on the NIH chronic prostatitis symptom index (NIH-CPSI), traditional Chinese medicine (TCM) syndrome score, and leukocyte count in the expressed prostatic secretion (EPS), we evaluated the results of treatment.

RESULTSTotally 238 patients completed the treatment, including 108 IIIA and 120 III B prostatitis cases. Before and after 4, 8, and 12 weeks of treatment, the total NIH-CPSI scores were 23.12 ± 6.99, 18.22 ± 6.39, 14.12 ± 5.88, and 12.36 ± 6.04 (P < 0.01) in the IIIA prostatitis patients and 22.01 ± 6.28, 17.56 ± 5.89, 13.67 ± 5.18, and 11.45 ± 5.22 in the III prostatitis patients (P < 0.01), the TCM syndrome scores were 52.12 ± 13.08, 48.13 ± 12.11, 43.05 ± 11.19, and 40.78 ± 10. 59 in the former (P < 0.01) and 53.02 ± 12.12, 49.32 ± 12.78, 44.01 ± 11.79, and 39.67 ± 10.26 in the latter (P < 0.01), and the leukocyte counts were 26.09 ± 21.55, 23.02 ± 18.61, 18.25 ± 17.79, and 15.36 ± 16.38 in the IIIA cases (P < 0.01). Neither abnormalities in liver and renal function nor obvious adverse events were observed during the experiment.

CONCLUSIONLongjintonglin Capsule, with its advantages of safety, effectiveness, and no obvious adverse reactions in the treatment of type III prostatitis, deserves to be recommended for clinical application.

Administration, Oral ; Adult ; Capsules ; Chronic Pain ; drug therapy ; Drug Administration Schedule ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Male ; Middle Aged ; Pelvic Pain ; drug therapy ; Phytotherapy ; Prostatitis ; drug therapy ; Syndrome